GSK Bio
NEWS
Moncef Slaoui was fired as chairman of the board of directors of Galvani Bioelectronics following allegations of sexual harassment and inappropriate conduct.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Multiple pharmaceutical companies struck large licensing deals with one another this week. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
The drug is a lipoglycopeptide antibiotic. It is given in a single, one-hour infusion.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
Genentech reported its rheumatoid arthritis drug Actemra failed to hit its primary endpoint in a COVID-19 trial, while Vir and GlaxoSmithKline’s antibody against COVID-19 demonstrated 85% efficacy.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
JOBS
IN THE PRESS